The CEO Dr. Neinar Seli and Professor Mati Karelson presented Chemestmed’s groundbreaking results on unique proprietary RNA m6A activators in neuroscience titled as “Neuroprotective agents based on RNA m6A regulation”
Chemestmed, Ltd. and Admescope OY (Finland) signed the service agreements on the in vivo pharmacokinetics of two compounds after oral and IV administration to mice and rats.
